Date: 2015-04-01
Type of information: Nomination
Compound:
Company: 4SC (Germany)
Therapeutic area: Autoimmune diseases - Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On April 1, 2015, 4SC, a discovery and development company of targeted small molecule drugs for cancer and autoimmune diseases, announced the appointment of Dr Susanne Danhauser-Riedl as the Company\'s Chief Medical Officer (CMO). Dr Danhauser-Riedl will take over management of clinical development at 4SC AG from 1 April 2015 and thus assume responsibility for the further clinical development of the Company\'s oncology pipeline, including the compounds resminostat, 4SC-202 and 4SC-205. As Chief Medical Officer, she will report directly to Management Board Member and Chief Development Officer (CDO) & Chief Scientific Officer (CSO) Dr Daniel Vitt. Dr Susanne Danhauser-Riedl is a medical doctor and has long standing experience in the fields of haematology and oncology. She has over 20 years of management experience both in research and clinical practice and in the fields of Medical Affairs and clinical development in the pharmaceutical industry. Prior to joining 4SC, she spent almost ten years at GSK. At GSK she held responsibility for the complete Life Cycle Management including clinical development of the oncology portfolio in Germany serving as Medical Head Haematology/Oncology and, from 2012, as Medical Head Haematology/Head Regional Medical Advisors. Before joining GSK, Dr Danhauser-Riedl spent four years in the field of Medical Affairs at MedacSchering Onkologie GmbH, most recently as Head of Medical Affairs and Drug Safety.
Financial terms:
Latest news:
